Plasma levels of IFN-γ and IL-4 in untreated ITP patients, patients after HD-DXM therapy, and healthy controls. Levels of plasma IFN-γ and IL-4 were determined by ELISA. Elevated plasma IFN-γ level, and decreased IL-4 level was detected in untreated ITP patients compared with patients after HD-DXM therapy (IFN-γ: 62.7 ± 13.0 vs 40.3 ± 11.0 pg/mL, P < .001; IL-4: 8.9 ± 2.7 vs 18.5 ± 4.2 pg/mL, P < .001, respectively) or healthy controls (37.4 ± 4.8 pg/mL, P < .001; and 18.3 ± 4.7 pg/mL, P < .001, respectively). There was no significant difference in plasma IFN-γ or IL-4 levels between posttreatment ITP patients and healthy controls (P > .05). *P < .001.